Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Melanoma 1Immunologic Deficiency Syndromes 1IgA Deficiency 1

Interventions

fludarabine phosphate 5fludarabine 4Whole-Body Irradiation 4Melphalan 4Cyclophosphamide 4Thiotepa 3Busulfan 3Blood Specimen Collection 3Antilymphocyte Serum 3Alemtuzumab 3plerixafor 2Therapeutics 2Cyclosporins 2Cyclosporine 2thymoglobulin 1fosphenytoin 1Voriconazole 1Vaccination 1Tacrolimus 1Photopheresis 1Phlebotomy 1Phenytoin 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Mesna 1Injections 1Influenza Vaccines 1Honey 1Holistic Health 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunologic Deficiency Syndromes × B-Cell Activating Factor × Clear all
NCT00024934 2016-09-22

B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
20 enrolled

Immunologic Deficiency Syndromes, Neoplasms, IgA Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡